Scarica l'app Stockscreener
27.70
8.69%
2.215
Dopo l'orario di chiusura:
27.60
-0.10
-0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$25.48
Aprire:
$25.58
Volume 24 ore:
16.50M
Relative Volume:
1.48
Capitalizzazione di mercato:
$10.82B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.173
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+6.62%
1M Prestazione:
+17.57%
6M Prestazione:
+6.05%
1 anno Prestazione:
-35.49%
Intervallo 1D:
$25.38
$27.75
Intervallo di 1 settimana:
$23.92
$27.75
Portata 52W:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.70 | 9.96B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Finviz
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Ames Tribune
Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average - Finviz
Skandinaviska Enskilda Banken AB publ Trims Position in Moderna, Inc. $MRNA - MarketBeat
Norges Bank Buys Shares of 3,439,999 Moderna, Inc. $MRNA - MarketBeat
Former FDA commissioners castigate plan to change vaccine approval standards - Seeking Alpha
Moderna to Present at Upcoming Investor Conferences in March 2024 - ACCESS Newswire
Moderna In Crisis? FDA Memo Ties Vaccines To Deaths, Stock Tumbles! - Smartkarma
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Seasonal Vaccines Market Accelerating Growth and Rising Opportunities Through 2035 - GlobeNewswire Inc.
CapEx per share of Moderna, Inc. – DUS:0QF - TradingView
The FDA’s Leaked Covid Memo Is Reckless and Dangerous - Bloomberg.com
Moderna, Inc. $MRNA Shares Sold by Hsbc Holdings PLC - MarketBeat
Goodwin Advises Moderna With Its $1.5 Billion Five-Year Credit Facility From Ares Management - Mondaq
Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards - Yahoo Finance
Officer Klinger Acquires 120 Of Moderna Inc [MRNA] - TradingView
Pres Hoge Acquires 336 Of Moderna Inc [MRNA] - TradingView
MVP: Williams & Connolly's David M. Krinsky - Law360
Transcript : Moderna, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 11 - MarketScreener
Moderna (MRNA) Responds to FDA Claims Regarding Vaccine Safety - GuruFocus
Prudential Financial Inc. Boosts Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc.: Dividend historical data and projections - MarketScreener
Is Moderna Stock Underperforming the Nasdaq? - Yahoo Finance
Tougher FDA Rules on Vaccine Approval Might Change the Case for Investing in Moderna (MRNA) - Yahoo Finance
Moderna, Novavax Shares Fall on News FDA Plans to Tighten Vaccine Approvals - The Wall Street Journal
Moderna stock falls after FDA vows to impose new vaccine requirements - The Boston Globe
S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership - Investopedia
Moderna, Other Pharma Stocks Close Lower After US FDA Reportedly Plans to Toughen Vaccine Approval - marketscreener.com
Moderna Falls As FDA Vows To Impose New Vaccine Rules - MarketScreener
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks - Investopedia
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - MSN
Moderna stock slides as FDA moves to tighten vaccine guidelines - Proactive financial news
Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More - Investopedia
Moderna (MRNA) Shares Drop Amid Stricter FDA Vaccine Approval St - GuruFocus
Stock Movers: Moderna, Synopsys, Barrick Mining - Bloomberg.com
Moderna and Novavax Stocks Drop as FDA Outlines Stricter Vaccine Approvals - Barron's
Moderna falls after FDA vows to impose new vaccine requirements - The Detroit News
Moderna, vaccine makers decline following FDA official comments on future approvals (MRNA:NASDAQ) - Seeking Alpha
Moderna Stock Drops as FDA Signals New Restrictions on Vaccine Approvals - Tokenist
Here’s why Moderna is sliding - Traders Union
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals - Barron's
Moderna Falls as FDA Vows to Impose New Vaccine Requirements - Yahoo Finance
Market movers: Charbone Hydrogen, Moderna, Synopsys... - Proactive financial news
Moderna Falls After FDA Vows to Impose New Vaccine Requirements - Bloomberg.com
Quadrature Capital Ltd Cuts Stake in Moderna, Inc. $MRNA - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Sells 508,235 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Moderna (MRNA) Leads Healthcare Gains with 16.19% Surge - GuruFocus
Rhumbline Advisers Acquires 25,390 Shares of Moderna, Inc. $MRNA - MarketBeat
FDA's Prasad Cites Alleged Child COVID Shot Deaths in Push for Stricter Rules - Benzinga
FDA official Prasad says COVID shot deaths mean stricter vaccine approval standards - Seeking Alpha
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.44%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):